Amarin Corp Plc (AMRN)

[sts66]

Thnx - after I quit reading the board yesterday I found that on my own somehow and was so disgusted by what I read I was too mad to come back here and list all the BS I found, which others have noted is really long - as in almost every section of that doc questions R-IT results and they conclude there is no UK population that would benefit from V, and it appears the cost was a huge part of their problem:

It noted the company’s base case results were all above £20,000 per QALY gained

They actually set a price on what a person's life is worth? I guarantee you there are drugs the NHS covers that have higher costs per QALY. And this document does not appear to take savings to the health care system from keeping people out of the hospital into account either - it's a totally one-sided opinion on the value of V.

There's also some memory in the back of my brain from years ago that says the UK pays special attention and gives greater scrutiny to a new drug that would cost the NHS more than a certain amount of money per year (QALY is not the sole consideration), and the number I recall was something like only $60M USD - that may not be correct, but the cost was shockingly low, and I cannot rediscover the document I found that in, think it was buried deep within the NHS or NICE website. The poor view of this committee on the value of V makes me believe the annual cost of V is expected to be well above that number, so they are trying to find every reason to not endorse V.

Ok, just spent half an hour trying to find that doc again - didn't find the exact one I recall reading, but this one is just as good - in 2017 NICE and the NHS introduced a ‘budget impact test’, to assess the level of the affordability challenge that new drugs pose - and the magic number isn't $60M USD, it's only £20m or more per year!

https://www.nice.org.uk/news/feature/changes-to-nice-drug-appraisals-what-you-need-to-know

If my math is right, and assuming the cost of a month of V is $240 like KM has mentioned, if more than 9,375 people in the UK are prescribed V, the total annual cost to the NHS will exceed £20m/yr - this is why that group doesn't believe V is worth the cost even though they don't come out and say it.